TriBsyn

TriBsyn is a proprietary branded ingredient developed and exclusively offered by Natural Alternatives International (NAI) under the CarnoSyn Brands portfolio. The product represents a significant advancement in beta-alanine supplementation technology, targeting the sports nutrition, health and wellness, and medical foods markets. At its core, TriBsyn is a patent-pending carnosine booster that utilizes a proprietary Hydro Oleo technology to increase beta-alanine bioavailability by more than four times compared to conventional beta-alanine, while simultaneously eliminating the common paresthesia (tingling) sensation that has historically limited widespread consumer adoption.

The ingredient is positioned as a versatile fine powder format, offering formulators enhanced flexibility to incorporate it across a wide range of delivery systems and product types, including dietary supplements, fortified foods, and medical foods. Its reduced input requirement — achieving efficacious dosing with significantly less beta-alanine — makes it an attractive option for manufacturers seeking cost-effective, high-performance ingredients. Clinical validation comes from a double-blind, three-way crossover study confirming both the elimination of paresthesia and superior pharmacokinetic efficiency at tested dosages.

TriBsyn is particularly well-suited to address health challenges associated with aging populations and individuals using GLP-1 receptor agonists, a growing consumer segment experiencing muscle mass loss and cognitive decline as side effects of these therapies. The ingredient supports muscle function and working capacity, cognitive performance, mental fatigue reduction, and slows age-related physiological changes by increasing carnosine levels in muscle tissue.

The scientific foundation underpinning TriBsyn draws from the extensive clinical research base established by CarnoSyn Brands over many years. CarnoSyn beta-alanine, which is featured in TriBsyn, holds both New Dietary Ingredient (NDI) status from the FDA and Self-Affirmed Generally Recognized as Safe (GRAS) status — the only beta-alanine ingredient to have achieved both designations. This dual regulatory recognition underscores the rigorous safety, efficacy, and toxicology testing applied across the CarnoSyn Brands portfolio.

NAI, the parent entity, owns all relevant patents and trademarks associated with TriBsyn, CarnoSyn, and SR CarnoSyn. The broader CarnoSyn Brands portfolio includes CarnoSyn instant release beta-alanine powder and SR CarnoSyn sustained-release beta-alanine tablets, with TriBsyn representing the newest and most technologically advanced addition. The company serves professional athletes, active adults, seniors, and wellness-focused consumers, as well as B2B customers including supplement brands and functional food manufacturers seeking clinically backed, regulatory-compliant ingredient solutions.

The Nombase Funding database has 4,288 records from over 1,788 companies.

There's no funding data for this company.